156 terminated. 156 Phase 1, 46 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 156 | Terminated 156 |
| Phase 2 | 46 | Terminated 46 |
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination CAR-T Cell Therapy Targeting Hematological Malignancies 4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-08-01 | 2026-10-30 |
| A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) AUR104 - Select Relapsed/Refractory Lymphoid Malignancies | Phase 1 | Terminated | Aurigene Discovery Technologies Limited | 9 | 2024-12-12 | 2026-04-17 |
| Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-26 | 2025-08-03 |
| A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies BGB-21447 - Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 1 | Terminated | BeOne Medicines | 51 | 2023-06-20 | 2026-07-14 |
| A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL ONO-7018 - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Terminated | Ono Pharmaceutical Co., Ltd. | 9 | 2023-02-13 | 2026-05-29 |
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 8 | 2023-02-06 | 2024-07-18 |
| Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax Pirtobrutinib, Venetoclax - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2022-11-16 | 2025-12-15 |
| RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia RP-3500, Olaparib - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | University of Utah | 5 | 2022-09-23 | 2025-06-03 |
| A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma BMS-986403, Fludarabine, Cyclophosphamide - Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma | Phase 1 | Terminated | Bristol-Myers Squibb | 5 | 2022-09-14 | 2023-07-18 |
| CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies 0.75x10^6 cells/kg CAR20.19.22 cells, 1x10^6 cells/kg CAR20.19.22 cells, 2.5x10^6 cells/kg CAR20.19.22 cells - B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Medical College of Wisconsin | 4 | 2022-06-30 | 2024-09-19 |
| Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL MB-106 - Follicular B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma Recurrent | Phase 1 / Phase 2 | Terminated | Mustang Bio | 20 | 2022-05-24 | 2024-07-22 |
| A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL MS-553 - Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Terminated | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. | 13 | 2022-04-28 | 2024-07-18 |
| Study of XL114 in Subjects With Non-Hodgkin's Lymphoma XL114 - Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL) | Phase 1 | Terminated | Exelixis | 2 | 2022-04-12 | 2023-07-11 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies PRT1419, Azacitidine, Venetoclax - Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 21 | 2022-03-22 | 2024-01-31 |
| A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma GLPG5101 - Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell | Phase 1 / Phase 2 | Terminated | Lakefront Biotherapeutics NV | 130 | 2022-03-09 | 2026-06-30 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL BMF-219 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Biomea Fusion Inc. | 55 | 2022-01-24 | 2025-07-03 |
| A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome VIP152, BTKi - Relapsed Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Vincerx Pharma, Inc. | 6 | 2021-12-16 | 2023-11-18 |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) tafasitamab, parsaclisib - Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 54 | 2021-09-16 | 2026-02-04 |
| Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML LAVA-051, Interleukin 2 - Chronic Lymphocytic Leukemia, Multiple Myeloma | Phase 1 | Terminated | Lava Therapeutics | 16 | 2021-07-12 | 2025-01-27 |
| A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer Nivolumab, NKTR-214 - Ependymoma, Ewing Sarcoma | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 15 | 2021-06-03 | 2023-03-24 |
Showing 20 of 156. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (153) · Lymphoma, Non-Hodgkin (66) · Lymphoma, Mantle-Cell (58) · Lymphoma, Follicular (56) · Lymphoma, Large B-Cell, Diffuse (54) · Lymphoma, B-Cell, Marginal Zone (49) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (49) · Leukemia (36) · Lymphoma (36) · Burkitt Lymphoma (35) · Waldenstrom Macroglobulinemia (29) · Hodgkin Disease (28) · Lymphoma, Large-Cell, Immunoblastic (27) · Leukemia, Myeloid, Acute (25) · Multiple Myeloma (24)
Hemic and Lymphatic Diseases (156) · Immune System Diseases (156) · Immunoproliferative Disorders (156) · Lymphatic Diseases (156) · Neoplasms by Histologic Type (156) · Hematologic Diseases (155) · Lymphoproliferative Disorders (155) · Disease Attributes (154) · Pathologic Processes (154) · Pathological Conditions, Signs and Symptoms (154) · Chronic Disease (153) · Leukemia, Lymphoid (153) · Neoplasms (146) · Leukemia (120)
Rituximab (25) · Cyclophosphamide (11) · Lenalidomide (10) · venetoclax (8) · fludarabine (7) · fludarabine phosphate (7) · ibrutinib (6) · tanespimycin (6) · Bendamustine Hydrochloride (5) · Bortezomib (5) · Filgrastim (5) · idelalisib (5) · obinutuzumab (5) · Clofarabine (4) · Dasatinib (4)
National Cancer Institute (NCI) (22) · Gilead Sciences (7) · M.D. Anderson Cancer Center (7) · Masonic Cancer Center, University of Minnesota (5) · Novartis Pharmaceuticals (4) · Case Comprehensive Cancer Center (3) · TG Therapeutics, Inc. (3) · University of Medicine and Dentistry of New Jersey (3) · Aptose Biosciences Inc. (2) · Barbara Ann Karmanos Cancer Institute (2) · Biogen (2) · Bristol-Myers Squibb (2) · City of Hope Medical Center (2) · Emory University (2) · Exelixis (2)
United States (136) · Spain (16) · France (8) · Italy (8) · Canada (7) · Israel (6) · Poland (6) · Australia (5) · China (5) · Belgium (4) · Germany (4) · Netherlands (4) · Austria (3) · Finland (3) · Czechia (2)
Roger Strair, MD, PhD (3) · Abhinav Deol, M.D. (2) · Ajay Gopal (2) · Jeffrey Jones (2) · Rafael Bejar, MD, PhD (2) · William Wegener, MD, PhD (2) · Adam Petrich, MD (1) · Alessandra Ferrajoli, MD (1) · Andreas K Klein, MD (1) · Andres Forero-Torres, MD, CSU (1) · Asher Chanan-Khan (1)
PMID 34398557, PMID 23256542, PMID 23393050, PMID 24241210, PMID 24615776, PMID 24615777, PMID 24615778, PMID 26472751, PMID 27118540, PMID 29141948, PMID 29296805, PMID 29610115, PMID 30444200, PMID 30962222, PMID 31443741, PMID 31471376, PMID 31723767, PMID 33171487, PMID 33357452, PMID 33451977, PMID 33832946, PMID 34515338, PMID 35835137, PMID 36597128, PMID 36841672, PMID 36865133, PMID 36873868, PMID 37871300, PMID 37882668, PMID 38517235, PMID 38871487, PMID 39705540, PMID 39798981, PMID 39863139, PMID 40209059, PMID 40809193, PMID 42660131, PMID 42782312
U01CA076576 (5), P30CA015083 (3), P30CA016058 (3), P30CA072720 (3), 2014 (2), 2018 (2), 2019 (2), P30CA043703 (2), U01CA069912 (2), 2015 (1), 2017 (1), 2025 (1), N01CM00070 (1), P01CA044991 (1), P01CA065493 (1)